Changes in Hong Kong stocks | CSPC Group (01093) rose more than 4%, and Chairman Cai Dongchen added SYH2085 tablets to be approved for clinical trials in China

The Zhitong Finance App learned that CSPC Group (01093) rose by more than 4%. As of press release, it had risen 4.12% to HK$8.59, with a turnover of HK$443 million.

According to the news, the latest data from the Hong Kong Stock Exchange shows that on December 22, Chairman and Executive Director Cai Dongchen increased his holdings of CSPC Group by 13.454 million shares, at a price of HK$81,957 each, for a total amount of about HK$110 million. After the increase in holdings, the latest number of shares held was approximately 2.91 billion shares, and the latest shareholding ratio was 25.26%.

Recently, CSPC Group announced that the SYH2085 tablets developed by the Group have been approved by the State Drug Administration of the People's Republic of China and can conduct clinical trials in China. This product is an innovative chemical class 1 drug independently developed by the Group. It is a novel oral small molecule drug candidate that can inhibit the activity of RNA polymerase acid acid protein (PA) endonuclease in influenza viruses. The clinical indications approved this time are for the treatment of simple influenza A and B in adults and adolescents aged 12 and above.

This product is expected to become an effective drug for treating influenza, has high clinical development value, and will further enrich the Group's product pipeline in the field of anti-infective treatment.